Immutep is a clinical-stage biotechnology company specializing in LAG-3 immunotherapy, which targets the Lymphocyte Activation Gene-3 (LAG-3) molecule to enhance the immune system's ability to combat cancer and autoimmune diseases. Their lead product, Eftilagimod Alpha (also known as IMP321), is a soluble LAG-3 protein designed to activate antigen-presenting cells (APCs), thereby stimulating both innate and adaptive immune responses. This innovative approach aims to improve clinical outcomes for patients with various solid tumors, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Efti has shown promising results in clinical trials, receiving Fast Track Designation from the FDA for its use in first-line therapies.

In addition to Eftilagimod Alpha, Immutep is advancing a diverse pipeline that includes both clinical-stage and earlier-stage candidates targeting LAG-3 for multiple therapeutic applications. Their research encompasses various combinations of LAG-3 therapies with established treatments, such as anti-PD-1 therapies and chemotherapy, to enhance efficacy. The company collaborates with major pharmaceutical partners, including Merck & Co. and Novartis, to further develop these therapies and maximize their potential in treating cancer and autoimmune diseases. Immutep's commitment to leveraging its LAG-3 expertise positions it as a leader in the evolving field of immunotherapy.

Australia

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related
immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to
leveraging its technology and expertise to bring innovative treatment options to market for patients and to
maximize value to shareholders.

Cancer

Immune System Diseases

Lung Diseases

Urogenital Diseases

Immutep

Non-small cell lung carcinoma

Eftilagimod alpha (LAG-3Ig or IMP321), a recombinant protein that may be used in combination with other agents to amplify a patient’s immune response. Eftilagimod alpha is a soluble LAG-3Ig fusion protein and an antigen presenting cell, or APC, activator boosting the immune system.

Eftilagimod Alpha (LAG-3lg or IMP321) (APC activating Soluble LAG-3 Protein) + Keytruda

Metastatic breast cancer to brain

Eftilagimod alpha (LAG-3Ig or IMP321), a recombinant protein that may be used in combination with other agents to amplify a patient’s immune response. Eftilagimod alpha is a soluble LAG-3Ig fusion protein and an antigen presenting cell, or APC, activator boosting the immune system.

Eftilagimod Alpha (LAG-3lg or IMP321) (APC activating Soluble LAG-3 Protein) 

Soft tissue sarcoma

Eftilagimod Alpha + Pembrolizumab

Head and neck cancer

Head and neck squamous cell carcinoma

Eftilagimod Alpha (LAG-3lg or IMP321) + Keytruda 

Solid tumor/s

Eftilagimod Alpha (LAG-3lg or IMP321) (APC activating Soluble LAG-3 Protein) and avelumab

Urothelial cancer

Eftilagimod Alpha (LAG-3lg or IMP321) (APC activating Soluble LAG-3 Protein) and avelumab 

Autoimmune disease

IMP761, a first-in-class immunosuppressive LAG-3 agonist antibody, has the potential to address the root cause of many autoimmune diseases by specifically silencing autoimmune memory T cells that accumulate at disease sites and restoring balance to the immune system. As published in the Journal of Immunology, encouraging pre-clinical in vivo and in vitro studies show IMP761 inhibits peptide-induced T cell proliferation, activation of human primary T cells, and an antigen-specific delayed-type hypersensitivity (DTH) reaction. Additional preclinical data in oligoarticular juvenile idiopathic arthritis (o-JIA) published in Pediatric Research details how IMP761 led to a decrease in a broad spectrum of effector cytokines in just 48 hours. This study also showed children with o-JIA have a skewed LAG-3 metabolism and suggested they can benefit from agonistic LAG-3 activity.

IMP761 (LAG-3 agonist) 

COVID-19

Eftilagimod alpha (LAG-3Ig or IMP321), a recombinant protein that may be used in combination with other agents to amplify a patient’s immune response. Eftilagimod alpha is a soluble LAG-3Ig fusion protein and an antigen presenting cell, or APC, activator boosting the immune system and is a possible COVID therapy.&nbsp;

Immutep

Company Details